Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Centessa Pharmaceuticals ( (CNTA) ) has provided an update.
Centessa Pharmaceuticals reported its financial results for the third quarter of 2025 and provided updates on its orexin receptor 2 (OX2R) agonist program. The company highlighted significant progress in its clinical trials, particularly with ORX750, which showed promising results in treating narcolepsy and idiopathic hypersomnia. The Phase 2a study of ORX750 demonstrated statistically significant improvements in wakefulness and daily functioning for patients, with plans to initiate a registrational program in early 2026. Additionally, ORX142 showed a highly differentiated profile in Phase 1 trials, and ORX489 is advancing in IND-enabling studies. Financially, Centessa reported a net loss of $54.9 million for the quarter, with cash reserves expected to fund operations into mid-2027.
The most recent analyst rating on (CNTA) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.
Spark’s Take on CNTA Stock
According to Spark, TipRanks’ AI Analyst, CNTA is a Underperform.
Centessa Pharmaceuticals has a low overall stock score due to significant financial challenges, including ongoing losses, negative cash flow, and a bearish technical outlook. The lack of profitability reflected in the negative P/E ratio further contributes to the low score. Investors should be cautious, considering the company’s need for additional funding to sustain operations in the capital-intensive biotechnology industry.
To see Spark’s full report on CNTA stock, click here.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals is a clinical-stage pharmaceutical company operating in the biotechnology industry. The company focuses on developing innovative therapies, particularly in the neuroscience sector, with a strong emphasis on orexin receptor agonists for treating sleep disorders such as narcolepsy and idiopathic hypersomnia.
Average Trading Volume: 1,119,679
Technical Sentiment Signal: Buy
Current Market Cap: $3.18B
See more data about CNTA stock on TipRanks’ Stock Analysis page.